Global Hormone Replacement Therapy Market Is Estimated To Be Valued At US$ 13,556.7 Million 2022 And Exhibit A CAGR Of 5.4% During The Forecast Period (2022-2030)
Hormone Replacement Therapy Market
When the body of the human being
is unable to manufacture enough hormones, hormone replacement therapy is used.
Menopause, hypothyroidism, male hypogonadism, and growth hormone deficiency
diseases are all treated with it. Hot flashes, night sweats, vaginal dryness,
soreness, itching, or burning during sex, bone loss, poor sex-drive, mood
swings, and irritability are indications that a person needs hormone
replacement medication.
When the body doesn't produce
enough natural hormones, hormone replacement therapy (HRT) uses hormones to
replace them. For instance, thyroid and human development hormone patients may
receive hormone replacement treatment. Additionally, HRT was typically
recommended to menopausal people to help with their side effects, such as hot
flushes, night sweats, restless influences, mental and genito-urinary issues
(urinary recurrence and vaginal dryness), as well as for the prevention of
osteoporosis. Additionally, a study of 2,000 American women aged 30 to 60 found
that about 47% of the population may experience the negative impacts of
hormonal imbalance by 2020.
Global
Hormone Replacement Therapy Market Is Estimated To Be Valued At US$ 13,556.7 Million In 2022 And Is
Expected To Exhibit A CAGR Of 5.4% During The Forecast Period (2022-2030).
The main factors that influence
the growth of the global market for hormone replacement treatment include the
prevalence of menopausal problems and an increase in women's awareness of
post-menopausal problems. The expansion of the hormone replacement therapy
industry is also expected to be significantly aided by new hormone replacement
therapy launches. However, negative effects of hormone replacement treatment
and the high cost of therapy are anticipated to restrain market growth during
the projected time period.
The Global Hormone Replacement Therapy Market is expected to be
significantly impacted by the COVID-19 pandemic. The use of hormone replacement
therapy in COVID-19-infected patients has been the subject of an increasing
number of investigational investigations. For instance, the endurance rate in
post-menopausal women infected with SARS-CoV-2 who were taking a regular dosage
of exogenous estradiol for post-menopausal complaints was considered as high,
according to the investigation paper published in BMC Medicine, 2020.
Additionally, Stony Brook
University began a stage 2 clinical study in April 2020 to examine the role of
oestrogen in reducing the severity of COVID-19 adverse effects in comparison to
standard care, with the administration of estradiol through a transdermal patch
for a brief period of 7 days.
Major players operating in the global hormone replacement therapy
market include Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer
AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical
Industries Ltd., Amgen, Inc., and Eli Lilly and Company.
Read the Press Release of Global
Hormone Replacement Therapy Market
Comments
Post a Comment